{"id":1017133,"date":"2026-11-05T03:39:05","date_gmt":"2026-11-05T08:39:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"modified":"2026-11-05T03:39:05","modified_gmt":"2026-11-05T08:39:05","slug":"larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","title":{"rendered":"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference"},"content":{"rendered":"
\n

BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company\u2019s management team will participate in a fireside chat and 1×1 investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place in Boston, MA from November 9-11, 2026.<\/p>\n

\n Details on the fireside chat can be found below. <\/strong>\n <\/p>\n

Date: Tuesday, November 10, 2026
Time: 10:00 AM EST
Webcast Link: https:\/\/event.summitcast.com\/view\/<\/a><\/p>\n

Following the conclusion of the fireside chat, a replay will be available for 30 days on the \u201cEvents and Presentations<\/a>\u201d page of Larimar\u2019s website.<\/p>\n

\n About Larimar Therapeutics<\/strong>
\n
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https:\/\/larimartx.com<\/a>.<\/p>\n

\n Investor Contact:<\/strong>
\n
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com<\/a>
(212) 915-2569<\/p>\n

\n Company Contact:<\/strong>
\n
Michael Celano
Chief Financial Officer
mcelano@larimartx.com<\/a>
(484) 414-2715<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company\u2019s management team will participate in a fireside chat and 1×1 investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place in Boston, MA from November 9-11, 2026. Details on the fireside chat can be found below. Date: Tuesday, November 10, 2026 Time: 10:00 AM EST Webcast Link: https:\/\/event.summitcast.com\/view\/ Following the conclusion of the fireside chat, a replay will be available for 30 days on the \u201cEvents and Presentations\u201d page of Larimar\u2019s website. About Larimar Therapeutics Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology … <\/p>\n

Continue reading “Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017133","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLarimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company\u2019s management team will participate in a fireside chat and 1×1 investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place in Boston, MA from November 9-11, 2026. Details on the fireside chat can be found below. Date: Tuesday, November 10, 2026 Time: 10:00 AM EST Webcast Link: https:\/\/event.summitcast.com\/view\/ Following the conclusion of the fireside chat, a replay will be available for 30 days on the \u201cEvents and Presentations\u201d page of Larimar\u2019s website. About Larimar Therapeutics Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology … Continue reading "Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T08:39:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDQxNiM3OTQ2MDY5IzUwMDA3Nzg4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference\",\"datePublished\":\"2026-11-05T08:39:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"},\"wordCount\":209,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDQxNiM3OTQ2MDY5IzUwMDA3Nzg4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\",\"name\":\"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDQxNiM3OTQ2MDY5IzUwMDA3Nzg4OQ==\",\"datePublished\":\"2026-11-05T08:39:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDQxNiM3OTQ2MDY5IzUwMDA3Nzg4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDQxNiM3OTQ2MDY5IzUwMDA3Nzg4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","og_locale":"en_US","og_type":"article","og_title":"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","og_description":"BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company\u2019s management team will participate in a fireside chat and 1×1 investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place in Boston, MA from November 9-11, 2026. Details on the fireside chat can be found below. Date: Tuesday, November 10, 2026 Time: 10:00 AM EST Webcast Link: https:\/\/event.summitcast.com\/view\/ Following the conclusion of the fireside chat, a replay will be available for 30 days on the \u201cEvents and Presentations\u201d page of Larimar\u2019s website. About Larimar Therapeutics Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology … Continue reading \"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T08:39:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDQxNiM3OTQ2MDY5IzUwMDA3Nzg4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference","datePublished":"2026-11-05T08:39:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"},"wordCount":209,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDQxNiM3OTQ2MDY5IzUwMDA3Nzg4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/","name":"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDQxNiM3OTQ2MDY5IzUwMDA3Nzg4OQ==","datePublished":"2026-11-05T08:39:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDQxNiM3OTQ2MDY5IzUwMDA3Nzg4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDQxNiM3OTQ2MDY5IzUwMDA3Nzg4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-to-participate-in-the-guggenheim-3rd-annual-healthcare-innovation-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017133"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017133\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}